Sorrento Therapeutics
Biotechnology, 4955 Directors Pl, San Diego, California, 92121, United States, 501-1000 Employees
Phone Number: 85********
Who is SORRENTO THERAPEUTICS
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical need...
Read More
-
Headquarters: 4955 Directors Pl, San Diego, California, 92121, United States
-
Date Founded: 2009
-
Employees: 501-1000
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 999990 |
Show More
Does something look wrong? Fix it. | View contact records from SORRENTO THERAPEUTICS
Sorrento Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to Sorrento Therapeutics
Allogene Therapeutics
-
201-500
-
$ 1 Million to 5 Million
Artiva Biotherapeutics
-
51-200
-
$ 10 Million to 25 Million
Mirati Therapeutics
-
201-500
-
$ 50 Million to 100 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Sorrento Therapeutics
Answer: Sorrento Therapeutics's headquarters are located at 4955 Directors Pl, San Diego, California, 92121, United States
Answer: Sorrento Therapeutics's phone number is 85********
Answer: Sorrento Therapeutics's official website is https://sorrentotherapeutics.com
Answer: Sorrento Therapeutics's revenue is $50 Million to $100 Million
Answer: Sorrento Therapeutics's SIC: 2836
Answer: Sorrento Therapeutics's NAICS: 999990
Answer: Sorrento Therapeutics has 501-1000 employees
Answer: Sorrento Therapeutics is in Biotechnology
Answer: Sorrento Therapeutics top competitors include: Allogene Therapeutics , Artiva Biotherapeutics , Mirati Therapeutics
Answer: Sorrento Therapeutics contact info: Phone number: 85******** Website: https://sorrentotherapeutics.com
Answer: Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MABTM library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-TTM), antibody-drug conjugates (ADCs), oncolytic virus (SeprehvecTM), lymphatic drug targeting (SOFUSA), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXATM. In response to the global SARS-CoV-2 (COVID-19) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSCTM, COVI-AMGTM, COVIDROPSTM, and COVI SHIELDTM, and diagnostic test solutions, such as COVISTIXTM and COVITRACKTM.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month